Call Now

Human B7-DC / PD-L2 / CD273 Protein (His Tag)

B7-DC,B7DC,bA574F11.2,Btdc,CD273,PD-L2,PDCD1L2,PDL2

Catalog Number P10292-H08H
Organism Species Human
Host Human Cells
Synonyms B7-DC,B7DC,bA574F11.2,Btdc,CD273,PD-L2,PDCD1L2,PDL2
Molecular Weight The recombinant human PD-L2 consists of 211 amino acids and predicts a molecular mass of 24 kDa. As a result of glycosylation, the apparent molecular mass of rh PD-L2 is approximately 40-45 kDa in SDS-PAGE under reducing conditions.
predicted N Leu 20
SDS-PAGE
Purity > 98 % as determined by SDS-PAGE
Protein Construction A DNA sequence encoding the extracellular domain (Met 1-Pro 219) of human PD-L2 (NP_079515.2) was expressed with a C-terminal polyhistidine tag.
Bio-activity Measured by its binding ability in a functional ELISA . Immobilized recombinant human PD-L2 at 1 μg/ml (100 μl/well) can bind recombinant human PD1 with a linear range of 7.8-1000 ng/ml .
Research Area Immunology |Innate Immunity |Monocytes/Macrophages |Co-stimulatory Molecules
Formulation Lyophilized from sterile PBS, pH 7.4
1. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
Background Programmed death ligand 2 (PD-L2), also referred to as B7-DC and CD273, is a member of the B7 family of proteins including B7-1, B7-2, B7-H2, B7-H1 (PD-L1), and B7-H3. PD-L2 is a type I membrane protein and structurally consists of an extracellular region containing one V-like and one C-like Ig domain, a transmembrane region, and a short cytoplasmic domain. PD-L2 is expressed on antigen presenting cells, placental endothelium and medullary thymic epithelial cells, and can be induced by LPS in B cells, INF-γ in monocytes, or LPS plus IFN-γ in dendritic cells. The CD28 and B7 protein families are critical regulators of immune responses. PD-L2 and PD-L1 are two ligands for PD-1, member of the CD28/CTLA4 family expressed on activated lymphoid cells, and thus provide signals for regulating T cell activation and immune tolerance. The interaction of B7-DC/PD-1 exhibited a 2-6-fold higher affinity compared with the interaction of B7-H1/PD-1.
Reference
  • Latchman Y, et al. (2001) PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2: 261-8.
  • Carreno BM, et al. (2005) Therapeutic opportunities in the B7/CD28 family of ligands and receptors. Curr Opin Pharmacol. 5(4): 424-30.
  • Radhakrishnan S, et al. (2007) B7-DC/PD-L2 cross-linking induces NF-kappaB-dependent protection of dendritic cells from cell death. J Immunol. 178(3): 1426-32.